Transitions launches Signature VII lenses with Chromea7 technology

Article

This new lens will replace Transitions Signature VI lenses when available in January 2014.

Las Vegas-Transitions Optical, Inc. has launched Transitions Signature VII lenses with Chromea7 technology. Available in early January 2014, Transitions Signature VII lenses will replace Transitions VI lenses in the Transitions family.

Transitions Optical developed Transitions Signature VII lenses to be more responsive in more situations, testing them in more than 200 conditions representing real-life lighting situations including various temperatures, weather conditions, and geographies. Transitions Signature VII lenses use the patented Chromea7 technology, an exclusive dye formulation that allows the lenses to be more reactive to indirect sunlight and reflected sunlight, and become even darker on hot days.

Transitions Signature VII lenses will be offered in gray and brown.

Visit TransitionsSignature.com order a free launch kit, after completing an online quiz on the site. The launch kit will include a product information sheet, frequently asked questions and answers, and technical product notes.

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.